Share Price and Basic Stock Data
Last Updated: January 28, 2026, 3:17 pm
| PEG Ratio | 3.46 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Astrazeneca Pharma India Ltd reported a market capitalization of ₹21,188 Cr, with a share price of ₹8,475. The company’s revenue from operations for FY 2025 stood at ₹1,716 Cr, reflecting significant growth from ₹1,296 Cr in FY 2024 and ₹1,003 Cr in FY 2023. The revenue trajectory shows a consistent upward trend, with quarterly sales increasing from ₹236 Cr in September 2022 to ₹311 Cr in September 2023, culminating in ₹388 Cr by June 2024. The trailing twelve months (TTM) revenue reached ₹2,006 Cr, indicating robust operational performance. This growth is likely driven by a diverse product portfolio and strategic market positioning within the pharmaceuticals sector, which is generally characterized by high barriers to entry and significant R&D investment. The company’s sales growth outpaces typical sector averages, which often hover around 10-15% annually, showcasing Astrazeneca’s competitive edge.
Profitability and Efficiency Metrics
The profitability of Astrazeneca Pharma India Ltd is evidenced by a reported net profit of ₹116 Cr for FY 2025, which reflects a decrease from ₹162 Cr in FY 2024 but remains higher than ₹99 Cr in FY 2023. The operating profit margin (OPM) for FY 2025 stood at 15%, indicating effective cost management despite challenges in maintaining profitability. The company’s return on equity (ROE) was reported at 23.6%, while return on capital employed (ROCE) rose to 33.4%, both of which are significantly higher than typical sector averages, indicating efficient utilization of capital. The interest coverage ratio (ICR) reported at 201.78x highlights Astrazeneca’s strong ability to cover interest expenses, underscoring financial stability. However, the operating profit margin fluctuated over recent quarters, with a notable dip to 5% in December 2023, suggesting potential operational challenges that need addressing.
Balance Sheet Strength and Financial Ratios
Astrazeneca’s balance sheet reflects resilience, with total assets reported at ₹1,518 Cr for FY 2025, up from ₹1,078 Cr in FY 2024. The company’s reserves increased to ₹794 Cr, showcasing a solid capital base to support future growth. Borrowings remained low at ₹35 Cr, indicating prudent financial management and minimal reliance on debt financing, which aligns with its interest coverage ratio. The price-to-book value (P/BV) ratio stood at 27.93x, suggesting the stock is highly valued relative to its book value, which indicates strong market confidence but may also imply overvaluation risks. The current ratio of 1.91x illustrates good liquidity, while the quick ratio at 1.13x shows that the company can meet its short-term liabilities without needing to sell inventory. Overall, these financial ratios suggest a robust balance sheet, but the high P/BV raises questions about sustainability if growth slows.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Astrazeneca Pharma India Ltd indicates strong promoter confidence, with promoters holding 75% of the equity. This stability is complemented by foreign institutional investors (FIIs) holding 2.74% and domestic institutional investors (DIIs) at 5.26%, reflecting cautious but present interest from institutional investors. The public shareholding stood at 17%, down from 20.97% in December 2022, which may suggest a consolidation phase among larger shareholders. Additionally, the number of shareholders decreased to 32,914, indicating a trend where larger investors are taking more substantial positions. The dividend payout ratio for FY 2025 was reported at 69%, demonstrating a commitment to returning value to shareholders, although this is a decline from previous years. This pattern may signal potential concerns regarding future cash flows as the company balances reinvestment and shareholder returns.
Outlook, Risks, and Final Insight
Looking ahead, Astrazeneca Pharma India Ltd must navigate several risks, including market competition and potential regulatory challenges that could impact growth. The company’s historical revenue growth positions it well, but maintaining momentum in a sector susceptible to pricing pressures and generic competition poses challenges. Additionally, operational efficiency must be prioritized to counteract fluctuations in profit margins. On the positive side, Astrazeneca’s strong balance sheet and high ROCE present opportunities for strategic investments and continued innovation. If the company successfully addresses operational efficiency and market dynamics, it could leverage its strong market position to enhance profitability. Conversely, failure to manage these risks may lead to a decline in investor confidence and stock valuation, necessitating vigilant financial oversight and strategic agility.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 128 Cr. | 102 | 197/84.3 | 28.4 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.21 Cr. | 1.68 | 4.29/1.68 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 3,405 Cr. | 312 | 479/192 | 70.5 | 24.3 | 0.22 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 34.9 Cr. | 47.0 | 82.8/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 66.5 Cr. | 45.4 | 45.8/17.0 | 158 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 19,524.54 Cr | 1,087.39 | 47.65 | 202.32 | 0.38% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 236 | 250 | 285 | 295 | 311 | 306 | 383 | 388 | 408 | 440 | 480 | 526 | 559 |
| Expenses | 195 | 213 | 225 | 228 | 258 | 291 | 334 | 349 | 355 | 363 | 394 | 445 | 484 |
| Operating Profit | 41 | 37 | 60 | 67 | 53 | 15 | 49 | 38 | 53 | 77 | 86 | 81 | 75 |
| OPM % | 17% | 15% | 21% | 23% | 17% | 5% | 13% | 10% | 13% | 17% | 18% | 15% | 13% |
| Other Income | 7 | 7 | -32 | 8 | 25 | 10 | 9 | -49 | 8 | -26 | 10 | 11 | 1 |
| Interest | 0 | 0 | 0 | 0 | 0 | 1 | -0 | 0 | 0 | 0 | 1 | 1 | 1 |
| Depreciation | 3 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 9 | 9 | 18 | 17 | 3 |
| Profit before tax | 44 | 39 | 23 | 71 | 73 | 20 | 54 | -15 | 51 | 42 | 78 | 75 | 73 |
| Tax % | 26% | 26% | 26% | 25% | 29% | 23% | 27% | -22% | 25% | 27% | 26% | 25% | 26% |
| Net Profit | 33 | 29 | 17 | 54 | 52 | 16 | 39 | -12 | 38 | 31 | 58 | 56 | 54 |
| EPS in Rs | 13.02 | 11.72 | 6.91 | 21.54 | 20.95 | 6.32 | 15.79 | -4.72 | 15.37 | 12.34 | 23.30 | 22.33 | 21.69 |
Last Updated: January 2, 2026, 9:31 am
Below is a detailed analysis of the quarterly data for Astrazeneca Pharma India Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 559.00 Cr.. The value appears strong and on an upward trend. It has increased from 526.00 Cr. (Jun 2025) to 559.00 Cr., marking an increase of 33.00 Cr..
- For Expenses, as of Sep 2025, the value is 484.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 445.00 Cr. (Jun 2025) to 484.00 Cr., marking an increase of 39.00 Cr..
- For Operating Profit, as of Sep 2025, the value is 75.00 Cr.. The value appears to be declining and may need further review. It has decreased from 81.00 Cr. (Jun 2025) to 75.00 Cr., marking a decrease of 6.00 Cr..
- For OPM %, as of Sep 2025, the value is 13.00%. The value appears to be declining and may need further review. It has decreased from 15.00% (Jun 2025) to 13.00%, marking a decrease of 2.00%.
- For Other Income, as of Sep 2025, the value is 1.00 Cr.. The value appears to be declining and may need further review. It has decreased from 11.00 Cr. (Jun 2025) to 1.00 Cr., marking a decrease of 10.00 Cr..
- For Interest, as of Sep 2025, the value is 1.00 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 1.00 Cr..
- For Depreciation, as of Sep 2025, the value is 3.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 17.00 Cr. (Jun 2025) to 3.00 Cr., marking a decrease of 14.00 Cr..
- For Profit before tax, as of Sep 2025, the value is 73.00 Cr.. The value appears to be declining and may need further review. It has decreased from 75.00 Cr. (Jun 2025) to 73.00 Cr., marking a decrease of 2.00 Cr..
- For Tax %, as of Sep 2025, the value is 26.00%. The value appears to be increasing, which may not be favorable. It has increased from 25.00% (Jun 2025) to 26.00%, marking an increase of 1.00%.
- For Net Profit, as of Sep 2025, the value is 54.00 Cr.. The value appears to be declining and may need further review. It has decreased from 56.00 Cr. (Jun 2025) to 54.00 Cr., marking a decrease of 2.00 Cr..
- For EPS in Rs, as of Sep 2025, the value is 21.69. The value appears to be declining and may need further review. It has decreased from 22.33 (Jun 2025) to 21.69, marking a decrease of 0.64.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 5:37 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 474 | 517 | 564 | 544 | 571 | 728 | 832 | 814 | 806 | 1,003 | 1,296 | 1,716 | 2,006 |
| Expenses | 487 | 528 | 547 | 506 | 525 | 657 | 711 | 678 | 719 | 838 | 1,111 | 1,462 | 1,687 |
| Operating Profit | -13 | -11 | 16 | 37 | 46 | 71 | 121 | 135 | 86 | 165 | 184 | 254 | 320 |
| OPM % | -3% | -2% | 3% | 7% | 8% | 10% | 15% | 17% | 11% | 16% | 14% | 15% | 16% |
| Other Income | 23 | 6 | 7 | 14 | 12 | 16 | 13 | 13 | 15 | -14 | 51 | -56 | -3 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 2 |
| Depreciation | 10 | 15 | 17 | 16 | 15 | 15 | 19 | 20 | 17 | 16 | 15 | 40 | 46 |
| Profit before tax | 0 | -21 | 6 | 36 | 44 | 73 | 114 | 127 | 83 | 134 | 220 | 156 | 268 |
| Tax % | 0% | 9% | 44% | 41% | 25% | 37% | 27% | 26% | 26% | 26% | 26% | ||
| Net Profit | -1 | -21 | 5 | 20 | 26 | 54 | 72 | 93 | 62 | 99 | 162 | 116 | 199 |
| EPS in Rs | -0.20 | -8.34 | 2.10 | 8.02 | 10.36 | 21.78 | 28.88 | 37.32 | 24.64 | 39.72 | 64.60 | 46.30 | 79.66 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 3% | 5% | 41% | 40% | 37% | 69% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -2000.00% | 123.81% | 300.00% | 30.00% | 107.69% | 33.33% | 29.17% | -33.33% | 59.68% | 63.64% | -28.40% |
| Change in YoY Net Profit Growth (%) | 0.00% | 2123.81% | 176.19% | -270.00% | 77.69% | -74.36% | -4.17% | -62.50% | 93.01% | 3.96% | -92.03% |
Astrazeneca Pharma India Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 13% |
| 5 Years: | 16% |
| 3 Years: | 29% |
| TTM: | 34% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 26% |
| 5 Years: | 19% |
| 3 Years: | 43% |
| TTM: | 61% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 23% |
| 5 Years: | 19% |
| 3 Years: | 44% |
| 1 Year: | 32% |
| Return on Equity | |
|---|---|
| 10 Years: | 19% |
| 5 Years: | 21% |
| 3 Years: | 23% |
| Last Year: | 24% |
Last Updated: September 4, 2025, 11:55 pm
Balance Sheet
Last Updated: December 4, 2025, 12:59 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
| Reserves | 167 | 146 | 151 | 218 | 242 | 296 | 359 | 451 | 506 | 584 | 707 | 765 | 794 |
| Borrowings | 0 | 0 | 0 | 0 | 0 | 0 | 12 | 12 | 9 | 7 | 5 | 36 | 35 |
| Other Liabilities | 244 | 261 | 247 | 193 | 214 | 261 | 330 | 306 | 337 | 389 | 362 | 712 | 781 |
| Total Liabilities | 416 | 412 | 403 | 415 | 461 | 562 | 706 | 775 | 857 | 985 | 1,078 | 1,518 | 1,615 |
| Fixed Assets | 94 | 101 | 97 | 87 | 75 | 75 | 72 | 81 | 74 | 69 | 67 | 64 | 40 |
| CWIP | 9 | 12 | 6 | 5 | 4 | 7 | 24 | 4 | 2 | 1 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 312 | 298 | 299 | 324 | 382 | 480 | 611 | 690 | 780 | 915 | 1,011 | 1,454 | 1,575 |
| Total Assets | 416 | 412 | 403 | 415 | 461 | 562 | 706 | 775 | 857 | 985 | 1,078 | 1,518 | 1,615 |
Below is a detailed analysis of the balance sheet data for Astrazeneca Pharma India Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 5.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 5.00 Cr..
- For Reserves, as of Sep 2025, the value is 794.00 Cr.. The value appears strong and on an upward trend. It has increased from 765.00 Cr. (Mar 2025) to 794.00 Cr., marking an increase of 29.00 Cr..
- For Borrowings, as of Sep 2025, the value is 35.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 36.00 Cr. (Mar 2025) to 35.00 Cr., marking a decrease of 1.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 781.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 712.00 Cr. (Mar 2025) to 781.00 Cr., marking an increase of 69.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 1,615.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,518.00 Cr. (Mar 2025) to 1,615.00 Cr., marking an increase of 97.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 40.00 Cr.. The value appears to be declining and may need further review. It has decreased from 64.00 Cr. (Mar 2025) to 40.00 Cr., marking a decrease of 24.00 Cr..
- For CWIP, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Investments, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Assets, as of Sep 2025, the value is 1,575.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,454.00 Cr. (Mar 2025) to 1,575.00 Cr., marking an increase of 121.00 Cr..
- For Total Assets, as of Sep 2025, the value is 1,615.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,518.00 Cr. (Mar 2025) to 1,615.00 Cr., marking an increase of 97.00 Cr..
Notably, the Reserves (794.00 Cr.) exceed the Borrowings (35.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -13.00 | -11.00 | 16.00 | 37.00 | 46.00 | 71.00 | 109.00 | 123.00 | 77.00 | 158.00 | 179.00 | 218.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 41 | 30 | 54 | 29 | 35 | 40 | 37 | 38 | 39 | 39 | 43 | 39 |
| Inventory Days | 210 | 157 | 141 | 121 | 229 | 186 | 197 | 198 | 164 | 193 | 140 | 208 |
| Days Payable | 241 | 203 | 174 | 184 | 257 | 266 | 251 | 221 | 223 | 231 | 121 | 173 |
| Cash Conversion Cycle | 10 | -16 | 21 | -34 | 7 | -39 | -17 | 15 | -20 | 1 | 62 | 74 |
| Working Capital Days | -45 | -15 | -28 | -36 | -8 | -14 | -16 | -17 | -34 | -18 | 20 | 22 |
| ROCE % | -12% | -13% | 4% | 15% | 19% | 27% | 34% | 30% | 16% | 31% | 31% | 33% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| Nippon India Small Cap Fund | 658,075 | 0.87 | 594.18 | 645,850 | 2025-12-08 07:42:13 | 1.89% |
| Bandhan Large & Mid Cap Fund | 110,637 | 0.73 | 99.89 | 96,791 | 2026-01-25 00:09:50 | 14.31% |
| Bandhan Innovation Fund | 83,964 | 3.82 | 75.81 | N/A | N/A | N/A |
| Nippon India Pharma Fund | 62,568 | 0.68 | 56.49 | 11,561 | 2025-12-08 04:19:42 | 441.2% |
| ICICI Prudential Pharma Healthcare & Diagnostics (P.H.D) Fund | 55,021 | 0.77 | 49.68 | N/A | N/A | N/A |
| Baroda BNP Paribas Small Cap Fund | 32,200 | 2.38 | 29.07 | N/A | N/A | N/A |
| Baroda BNP Paribas Manufacturing Fund | 30,600 | 2.85 | 27.63 | N/A | N/A | N/A |
| ICICI Prudential Multicap Fund | 22,090 | 0.12 | 19.95 | N/A | N/A | N/A |
| Bandhan Aggressive Hybrid Fund | 20,044 | 1.15 | 18.1 | 18,833 | 2026-01-26 01:30:10 | 6.43% |
| ICICI Prudential Smallcap Fund | 18,870 | 0.2 | 17.04 | 9,703 | 2026-01-26 08:54:41 | 94.48% |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 |
| Basic EPS (Rs.) | 46.30 | 64.60 | 39.70 | 24.60 | 37.30 |
| Diluted EPS (Rs.) | 46.30 | 64.60 | 39.70 | 24.60 | 37.30 |
| Cash EPS (Rs.) | 62.29 | 70.58 | 46.22 | 31.42 | 45.37 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 308.14 | 284.77 | 235.48 | 204.56 | 182.47 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 308.14 | 284.77 | 235.48 | 204.56 | 182.47 |
| Dividend / Share (Rs.) | 32.00 | 24.00 | 16.00 | 10.00 | 2.00 |
| Revenue From Operations / Share (Rs.) | 686.52 | 518.21 | 401.19 | 322.24 | 325.42 |
| PBDIT / Share (Rs.) | 117.84 | 87.70 | 76.49 | 40.38 | 59.32 |
| PBIT / Share (Rs.) | 101.84 | 81.72 | 69.98 | 33.60 | 51.27 |
| PBT / Share (Rs.) | 62.54 | 87.82 | 53.64 | 33.22 | 50.84 |
| Net Profit / Share (Rs.) | 46.30 | 64.60 | 39.72 | 24.64 | 37.32 |
| PBDIT Margin (%) | 17.16 | 16.92 | 19.06 | 12.52 | 18.22 |
| PBIT Margin (%) | 14.83 | 15.77 | 17.44 | 10.42 | 15.75 |
| PBT Margin (%) | 9.11 | 16.94 | 13.37 | 10.30 | 15.62 |
| Net Profit Margin (%) | 6.74 | 12.46 | 9.89 | 7.64 | 11.46 |
| Return on Networth / Equity (%) | 15.02 | 22.68 | 16.86 | 12.04 | 20.45 |
| Return on Capital Employeed (%) | 31.23 | 28.34 | 29.11 | 16.03 | 27.20 |
| Return On Assets (%) | 7.62 | 14.98 | 10.08 | 7.19 | 12.04 |
| Asset Turnover Ratio (%) | 1.32 | 1.26 | 1.09 | 0.98 | 1.10 |
| Current Ratio (X) | 1.91 | 2.61 | 2.18 | 2.12 | 2.04 |
| Quick Ratio (X) | 1.13 | 1.97 | 1.68 | 1.70 | 1.51 |
| Inventory Turnover Ratio (X) | 4.42 | 0.61 | 0.51 | 0.59 | 0.59 |
| Dividend Payout Ratio (NP) (%) | 51.84 | 24.76 | 20.14 | 8.11 | 5.35 |
| Dividend Payout Ratio (CP) (%) | 38.52 | 22.66 | 17.30 | 6.36 | 4.40 |
| Earning Retention Ratio (%) | 48.16 | 75.24 | 79.86 | 91.89 | 94.65 |
| Cash Earning Retention Ratio (%) | 61.48 | 77.34 | 82.70 | 93.64 | 95.60 |
| Interest Coverage Ratio (X) | 201.78 | 182.71 | 303.52 | 106.25 | 136.06 |
| Interest Coverage Ratio (Post Tax) (X) | 146.57 | 121.90 | 222.46 | 65.84 | 86.60 |
| Enterprise Value (Cr.) | 20979.18 | 12795.16 | 7617.77 | 5940.17 | 7173.15 |
| EV / Net Operating Revenue (X) | 12.22 | 9.88 | 7.60 | 7.37 | 8.82 |
| EV / EBITDA (X) | 71.21 | 58.36 | 39.84 | 58.85 | 48.37 |
| MarketCap / Net Operating Revenue (X) | 12.54 | 10.27 | 8.09 | 7.93 | 9.25 |
| Retention Ratios (%) | 48.15 | 75.23 | 79.85 | 91.88 | 94.64 |
| Price / BV (X) | 27.93 | 18.68 | 13.79 | 12.49 | 16.50 |
| Price / Net Operating Revenue (X) | 12.54 | 10.27 | 8.09 | 7.93 | 9.25 |
| EarningsYield | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
After reviewing the key financial ratios for Astrazeneca Pharma India Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 2.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 2.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 46.30. This value is within the healthy range. It has decreased from 64.60 (Mar 24) to 46.30, marking a decrease of 18.30.
- For Diluted EPS (Rs.), as of Mar 25, the value is 46.30. This value is within the healthy range. It has decreased from 64.60 (Mar 24) to 46.30, marking a decrease of 18.30.
- For Cash EPS (Rs.), as of Mar 25, the value is 62.29. This value is within the healthy range. It has decreased from 70.58 (Mar 24) to 62.29, marking a decrease of 8.29.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 308.14. It has increased from 284.77 (Mar 24) to 308.14, marking an increase of 23.37.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 308.14. It has increased from 284.77 (Mar 24) to 308.14, marking an increase of 23.37.
- For Dividend / Share (Rs.), as of Mar 25, the value is 32.00. This value exceeds the healthy maximum of 3. It has increased from 24.00 (Mar 24) to 32.00, marking an increase of 8.00.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 686.52. It has increased from 518.21 (Mar 24) to 686.52, marking an increase of 168.31.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 117.84. This value is within the healthy range. It has increased from 87.70 (Mar 24) to 117.84, marking an increase of 30.14.
- For PBIT / Share (Rs.), as of Mar 25, the value is 101.84. This value is within the healthy range. It has increased from 81.72 (Mar 24) to 101.84, marking an increase of 20.12.
- For PBT / Share (Rs.), as of Mar 25, the value is 62.54. This value is within the healthy range. It has decreased from 87.82 (Mar 24) to 62.54, marking a decrease of 25.28.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 46.30. This value is within the healthy range. It has decreased from 64.60 (Mar 24) to 46.30, marking a decrease of 18.30.
- For PBDIT Margin (%), as of Mar 25, the value is 17.16. This value is within the healthy range. It has increased from 16.92 (Mar 24) to 17.16, marking an increase of 0.24.
- For PBIT Margin (%), as of Mar 25, the value is 14.83. This value is within the healthy range. It has decreased from 15.77 (Mar 24) to 14.83, marking a decrease of 0.94.
- For PBT Margin (%), as of Mar 25, the value is 9.11. This value is below the healthy minimum of 10. It has decreased from 16.94 (Mar 24) to 9.11, marking a decrease of 7.83.
- For Net Profit Margin (%), as of Mar 25, the value is 6.74. This value is within the healthy range. It has decreased from 12.46 (Mar 24) to 6.74, marking a decrease of 5.72.
- For Return on Networth / Equity (%), as of Mar 25, the value is 15.02. This value is within the healthy range. It has decreased from 22.68 (Mar 24) to 15.02, marking a decrease of 7.66.
- For Return on Capital Employeed (%), as of Mar 25, the value is 31.23. This value is within the healthy range. It has increased from 28.34 (Mar 24) to 31.23, marking an increase of 2.89.
- For Return On Assets (%), as of Mar 25, the value is 7.62. This value is within the healthy range. It has decreased from 14.98 (Mar 24) to 7.62, marking a decrease of 7.36.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 1.32. It has increased from 1.26 (Mar 24) to 1.32, marking an increase of 0.06.
- For Current Ratio (X), as of Mar 25, the value is 1.91. This value is within the healthy range. It has decreased from 2.61 (Mar 24) to 1.91, marking a decrease of 0.70.
- For Quick Ratio (X), as of Mar 25, the value is 1.13. This value is within the healthy range. It has decreased from 1.97 (Mar 24) to 1.13, marking a decrease of 0.84.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 4.42. This value is within the healthy range. It has increased from 0.61 (Mar 24) to 4.42, marking an increase of 3.81.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 51.84. This value exceeds the healthy maximum of 50. It has increased from 24.76 (Mar 24) to 51.84, marking an increase of 27.08.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 38.52. This value is within the healthy range. It has increased from 22.66 (Mar 24) to 38.52, marking an increase of 15.86.
- For Earning Retention Ratio (%), as of Mar 25, the value is 48.16. This value is within the healthy range. It has decreased from 75.24 (Mar 24) to 48.16, marking a decrease of 27.08.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 61.48. This value is within the healthy range. It has decreased from 77.34 (Mar 24) to 61.48, marking a decrease of 15.86.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 201.78. This value is within the healthy range. It has increased from 182.71 (Mar 24) to 201.78, marking an increase of 19.07.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 146.57. This value is within the healthy range. It has increased from 121.90 (Mar 24) to 146.57, marking an increase of 24.67.
- For Enterprise Value (Cr.), as of Mar 25, the value is 20,979.18. It has increased from 12,795.16 (Mar 24) to 20,979.18, marking an increase of 8,184.02.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 12.22. This value exceeds the healthy maximum of 3. It has increased from 9.88 (Mar 24) to 12.22, marking an increase of 2.34.
- For EV / EBITDA (X), as of Mar 25, the value is 71.21. This value exceeds the healthy maximum of 15. It has increased from 58.36 (Mar 24) to 71.21, marking an increase of 12.85.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 12.54. This value exceeds the healthy maximum of 3. It has increased from 10.27 (Mar 24) to 12.54, marking an increase of 2.27.
- For Retention Ratios (%), as of Mar 25, the value is 48.15. This value is within the healthy range. It has decreased from 75.23 (Mar 24) to 48.15, marking a decrease of 27.08.
- For Price / BV (X), as of Mar 25, the value is 27.93. This value exceeds the healthy maximum of 3. It has increased from 18.68 (Mar 24) to 27.93, marking an increase of 9.25.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 12.54. This value exceeds the healthy maximum of 3. It has increased from 10.27 (Mar 24) to 12.54, marking an increase of 2.27.
- For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Astrazeneca Pharma India Ltd:
- Net Profit Margin: 6.74%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 31.23% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 15.02% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 146.57
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.13
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 91.6 (Industry average Stock P/E: 47.65)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 6.74%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Block N1, 12th Floor, Bengaluru Karnataka 560045 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Ms. Shilpa Divekar Nirula | Chairperson & Independent Director |
| Mr. Praveen Rao Akkinepally | Managing Director |
| Ms. Bhavana Agrawal | Executive Director |
| Ms. Sylvia Lorena Varela Ramon | Non Executive Director |
| Ms. Hooi Bien Chuah | Non Executive Director |
| Mr. Jesus Javier Diaz-Ropero Esteso | Non Executive Director |
| Ms. Revathy Ashok | Independent Director |
| Ms. Monica Widhani | Independent Director |
FAQ
What is the intrinsic value of Astrazeneca Pharma India Ltd?
Astrazeneca Pharma India Ltd's intrinsic value (as of 28 January 2026) is ₹7024.49 which is 17.12% lower the current market price of ₹8,475.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹21,188 Cr. market cap, FY2025-2026 high/low of ₹10,691/6,502, reserves of ₹794 Cr, and liabilities of ₹1,615 Cr.
What is the Market Cap of Astrazeneca Pharma India Ltd?
The Market Cap of Astrazeneca Pharma India Ltd is 21,188 Cr..
What is the current Stock Price of Astrazeneca Pharma India Ltd as on 28 January 2026?
The current stock price of Astrazeneca Pharma India Ltd as on 28 January 2026 is ₹8,475.
What is the High / Low of Astrazeneca Pharma India Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Astrazeneca Pharma India Ltd stocks is ₹10,691/6,502.
What is the Stock P/E of Astrazeneca Pharma India Ltd?
The Stock P/E of Astrazeneca Pharma India Ltd is 91.6.
What is the Book Value of Astrazeneca Pharma India Ltd?
The Book Value of Astrazeneca Pharma India Ltd is 320.
What is the Dividend Yield of Astrazeneca Pharma India Ltd?
The Dividend Yield of Astrazeneca Pharma India Ltd is 0.38 %.
What is the ROCE of Astrazeneca Pharma India Ltd?
The ROCE of Astrazeneca Pharma India Ltd is 33.4 %.
What is the ROE of Astrazeneca Pharma India Ltd?
The ROE of Astrazeneca Pharma India Ltd is 23.6 %.
What is the Face Value of Astrazeneca Pharma India Ltd?
The Face Value of Astrazeneca Pharma India Ltd is 2.00.